0
0
Home » Pharmaceuticals

Clinical Trials in 2022 – A Preview of Trials Planned to Initiate and Estimated to Complete in 2022

This report provides a preview of clinical trials that are planned to be initiated and projected to be completed in 2022.

Scope

The clinical trials data used for these analyses were extracted from GlobalData’s Clinical Trials Database. The data included planned clinical trials with a start date from January 1 to December 31, 2022, captured in the database as of December 20, 2021. The planned trials were analyzed and segmented by phase, single versus multinational trials, geography, sponsor type (industry versus non-industry), therapy area, indication, top sponsors, molecule type, and top drug trials. Clinical trials with an ongoing or planned status with an end date between January 1 and December 31, 2022, were also examined. The trials that are estimated to be completed in 2022 were split by phase, status, indication, sponsor type, top sponsors, and geography. Additional analyses were completed for COVID-19 trials planned to be initiated or expected to be completed in 2022. In this report, a small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.

Reasons to Buy

Understand the planned trials landscape and trends for 2022

Provide early insight for studies expected to be completed in 2022

The trends of rescue clinical trials with delayed estimated end date

Analyses for COVID-19 trials planned to be initiated or expected to be completed in 2022

Table of Contents

Executive Summary

Introduction

Clinical Trials Planned to Initiate in 2022

Clinical Trials Estimated to Complete in 2022

Spotlight on COVID-19 Clinical Trials

Key Findings

Appendix

List of Figures

Figures 1 and 2: Planned Clinical Trials, by Phase and Sponsor Type

Figure 3: Planned Clinical Trials Top Industry Sponsors, by Phase

Figure 4: Planned Clinical Trials Top Non-Industry Sponsors, by Phase

Figure 5: Planned Clinical Trials Single Country or Multinational, by Sponsor Type and Phase

Figure 6: Planned Clinical Trials Regions, by Phase

Figure 7: Planned Clinical Trials Regions, by Phase and Distribution

Figure 8: Planned Clinical Trials Country, by Phase

Figure 9: Planned Clinical Trials Country, by Phase and Distribution

Figure 10 and 11: Planned Clinical Trials Primary Intervention Molecule Type, by Phase and Distribution

Figure 12: Planned Clinical Trials Top Therapy Areas, by Phase

Figure 13: Planned Clinical Trials Top Therapy Areas, by Phase and Distribution

Figure 14: Planned Clinical Trials Top Indications, by Phase

Figure 15: Planned Clinical Trials Top Indications, by Phase and Distribution

Figure 16: Estimated to Complete Clinical Trials, by Phase

Figure 17 and 18: Estimated to Complete Clinical Trials, by Status and Phase Distribution

Figure 19: Estimated to Complete Clinical Trials, by Sponsor Type and Phase

Figure 20: Estimated to Complete Clinical Trials, by Top Industry Sponsor

Figure 21: Estimated to Complete Clinical Trials, by Top Non-Industry Sponsor

Figure 22: Estimated to Complete Single Country or Multinational Clinical Trials, by Region

Figure 23: Estimated to Complete Clinical Trials, by Country

Figure 24: Estimated to Complete Clinical Trials, by Therapy Area

Figure 25: Estimated to Complete Clinical Trials, by Indication

Figure 26 and 27: Planned Clinical Trials for COVID-19, by Phase and Sponsor Type

Figure 28: Planned Clinical Trials for COVID-19, by Top Industry Sponsors

Figure 29: Planned Clinical Trials for COVID-19, by Top Non-Industry Sponsors

Figure 30 and 31: Planned Clinical Trials for COVID-19, by Molecule Type and Phase

Figure 32: Planned Clinical Trials for COVID-19 Single Country or Multinational, by Molecule Type

Figure 33: Planned Clinical Trials for COVID-19 for Therapeutics and Vaccines, by Region

Figure 34 and 35: Estimated to Complete COVID-19 Clinical Trials, by Status and Phase Distribution

Figure 36: Estimated to Complete Clinical Trials for COVID-19 vs Non-COVID Indications, by Status and Indication Distribution

Figure 37: Estimated to Complete Planned Clinical Trials for COVID-19 vs Non-COVID Indications, by Phase and Indication Distribution

    Pricing

Discounts available for multiple purchases.

reportstore@globaldata.com
+44 20 7947 2960

Join our mailing list

Saved reports